semaglutide and spironolactone + Semaglutide: Safety, Interactions & Monitoring – PlexusDx Atorvastatin and Spironolactone: Drug Interaction

Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials

Su, T., Xu, M., Lu, F

Change history 01 December 2021 A Correction to this paper has been published: Abbreviations App: Application BGAT: Blood glucose awareness training BGM: Blood glucose monitoring CGM: Continuous glucose monitoring COVID-19: Coronavirus disease-2019 DKA: Diabetic ketoacidosis DSMES: Diabetes self-management education and support EDIC: Epidemiology of Diabetes Interventions and Complications FDA: US Food and Drug Administration GLP-1 RA: Glucagon like peptide-1 receptor agonists GMI: Glucose management indicator IAH: Impaired awareness of hypoglycaemia is-CGM: Intermittently scanned continuous glucose monitoring MDI: Multiple daily injections PTA: Pancreas transplants alone rt-CGM: Real-time continuous glucose monitoring SGLT: Sodiumglucose cotransporter SPK: Simultaneous pancreas and kidney TBR: Time below range TIR: Time in range References Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ (2012) Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort

Tew KD, Bomber AM and Hoffman SJ